The Claim
In non-obese adults with type 2 diabetes, 12 weeks of daily ipragliflozin 50 mg does not significantly alter skeletal muscle mass or liver fat content.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In non-obese adults with type 2 diabetes, taking 50 mg of ipragliflozin daily for 12 weeks does not change skeletal muscle mass or liver fat content.
See the scientific wording
In non-obese adults with type 2 diabetes, 12 weeks of ipragliflozin 50 mg daily does not significantly alter skeletal muscle mass or liver fat content, suggesting a selective effect on adipose tissue without muscle or hepatic catabolism.
The drug blocks sugar reabsorption in the kidneys, causing sugar to leave the body in urine. This lowers blood sugar and insulin levels, which stops the body from storing fat in fat tissue and starts burning fat for energy. Fat around the heart and belly shrinks because it is more sensitive to this shift, but muscles and the liver do not lose mass because their energy needs are met by other sources.
What the research says
1 studyIn people with type 2 diabetes who aren’t overweight, taking this drug for 12 weeks lowered fat around the heart but didn’t reduce muscle or liver fat — meaning it targets fat tissue without harming muscle or worsening liver fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.